Generic drugmaker Mylan said it would buy Meda in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company. The move comes three months after Mylan ditched its seven-month long pursuit of smaller rival, Perrigo.

Mylan will finance the cash portion of the offer through a new bridge credit facility arranged by Deutsche Bank Securities and Goldman Sachs Bank USA. The transaction, due to be completed by the third quarter, is expected by Mylan to immediately add to earnings.

The Netherlands-based Mylan said the offer, recommended by Meda’s board, valued the company at $9.9 billion, including debt. Meda’s two largest shareholders, who own about 30% of the specialty pharmaceutical’s outstanding shares, have accepted the offer.